FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286293530> ?p ?o ?g. }

• W4286293530 endingPage "e19084" @default.
• W4286293530 startingPage "e19084" @default.
• W4286293530 abstract "e19084 Background: Midostaurin, an oral multikinase inhibitor including inhibition of KIT D816V, is approved for the treatment of advanced systemic mastocytosis (SM). Few studies have investigated the use of midostaurin in patients with advanced SM, but the data on its efficacy and safety in this population remains limited and uncertain. Therefore, we conducted this systematic review and meta-analysis to better assess the efficacy and safety of midostaurin in advanced SM. Methods: We systematically searched the following databases: PubMed/MEDLINE, Embase, and Cochrane through February 02, 2022, to include all studies that assessed the effect of midostaurin on clinical outcomes of patients with advanced SM. Our primary outcome was the overall response rate (ORR). The secondary outcomes included the rates of progressive disease (PD), stable disease (SD), and treatment discontinuation due to adverse events (AEs). All statistical analyses were performed using Open Meta Analyst (CEBM, University of Oxford). Pooled rates and corresponding 95% confidence intervals (CI) were calculated using DerSimonian-Laird/Random-effects approach. Results: Four studies (two clinical trials and two observational studies) with a total of 156 patients with advanced SM were included in the pooled analysis. The mean age of the patients was 59.6±15.8 years, and males represented 64.7% of total patients. The most common subtype of advanced SM was SM associated with hematological neoplasm (59%) followed by aggressive SM (23.1%). Three studies reported the KIT D816V mutation status, and 85.2% of patients were positive for KIT D816V mutation. The mean duration of treatment with midostaurin was 10±15.3 months. The pooled ORR was 60% (95% CI 46.5%-73.5%) over a mean follow-up duration of 41.1±38.7 months. The PD and SD rates were 12.8% (95% CI 7.6%-18%) and 10.6% (5.3%-15.9%), respectively. Treatment discontinuation due to AEs occurred in 25.6% (95% CI 18.8%-32.4%). The most common hematological grade ≥3 treatment-related AE was anemia (29%), while fatigue (7.1%) was the most common non-hematological grade ≥3 treatment-related AE. Conclusions: Our study demonstrated that midostaurin is very effective in patients with advanced SM with an acceptable safety profile. Our meta-analysis is hampered by a limited number of studies, a small sample size, and a lack of a control group. Future large-scale comparative studies are warranted to evaluate the efficacy and safety of midostaurin in these patients." @default.
• W4286293530 created "2022-07-21" @default.
• W4286293530 creator A5027306849 @default.
• W4286293530 creator A5034143108 @default.
• W4286293530 creator A5035061050 @default.
• W4286293530 creator A5039696256 @default.
• W4286293530 creator A5053308469 @default.
• W4286293530 creator A5059725250 @default.
• W4286293530 creator A5070380439 @default.
• W4286293530 date "2022-06-01" @default.
• W4286293530 modified "2023-09-27" @default.
• W4286293530 title "Midostaurin in advanced systemic mastocytosis: A systematic review and meta-analysis." @default.
• W4286293530 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e19084" @default.
• W4286293530 hasPublicationYear "2022" @default.
• W4286293530 type Work @default.
• W4286293530 citedByCount "0" @default.
• W4286293530 crossrefType "journal-article" @default.
• W4286293530 hasAuthorship W4286293530A5027306849 @default.
• W4286293530 hasAuthorship W4286293530A5034143108 @default.
• W4286293530 hasAuthorship W4286293530A5035061050 @default.
• W4286293530 hasAuthorship W4286293530A5039696256 @default.
• W4286293530 hasAuthorship W4286293530A5053308469 @default.
• W4286293530 hasAuthorship W4286293530A5059725250 @default.
• W4286293530 hasAuthorship W4286293530A5070380439 @default.
• W4286293530 hasConcept C126322002 @default.
• W4286293530 hasConcept C143998085 @default.
• W4286293530 hasConcept C197934379 @default.
• W4286293530 hasConcept C2776481607 @default.
• W4286293530 hasConcept C2778461978 @default.
• W4286293530 hasConcept C2778715236 @default.
• W4286293530 hasConcept C2779134260 @default.
• W4286293530 hasConcept C2780581156 @default.
• W4286293530 hasConcept C2908647359 @default.
• W4286293530 hasConcept C71924100 @default.
• W4286293530 hasConcept C95190672 @default.
• W4286293530 hasConcept C99454951 @default.
• W4286293530 hasConceptScore W4286293530C126322002 @default.
• W4286293530 hasConceptScore W4286293530C143998085 @default.
• W4286293530 hasConceptScore W4286293530C197934379 @default.
• W4286293530 hasConceptScore W4286293530C2776481607 @default.
• W4286293530 hasConceptScore W4286293530C2778461978 @default.
• W4286293530 hasConceptScore W4286293530C2778715236 @default.
• W4286293530 hasConceptScore W4286293530C2779134260 @default.
• W4286293530 hasConceptScore W4286293530C2780581156 @default.
• W4286293530 hasConceptScore W4286293530C2908647359 @default.
• W4286293530 hasConceptScore W4286293530C71924100 @default.
• W4286293530 hasConceptScore W4286293530C95190672 @default.
• W4286293530 hasConceptScore W4286293530C99454951 @default.
• W4286293530 hasIssue "16_suppl" @default.
• W4286293530 hasLocation W42862935301 @default.
• W4286293530 hasOpenAccess W4286293530 @default.
• W4286293530 hasPrimaryLocation W42862935301 @default.
• W4286293530 hasRelatedWork W2472403803 @default.
• W4286293530 hasRelatedWork W2766844642 @default.
• W4286293530 hasRelatedWork W2887445502 @default.
• W4286293530 hasRelatedWork W2912912825 @default.
• W4286293530 hasRelatedWork W2957984814 @default.
• W4286293530 hasRelatedWork W3157753956 @default.
• W4286293530 hasRelatedWork W3184652446 @default.
• W4286293530 hasRelatedWork W3202445121 @default.
• W4286293530 hasRelatedWork W3203938640 @default.
• W4286293530 hasRelatedWork W4298359609 @default.
• W4286293530 hasVolume "40" @default.
• W4286293530 isParatext "false" @default.
• W4286293530 isRetracted "false" @default.
• W4286293530 workType "article" @default.